Bio‑Techne Corporation announced the launch of Cultrex™ Synthetic Hydrogel on February 2 2026, a fully defined synthetic extracellular matrix that eliminates animal components and delivers consistent, scalable support for 3D stem cell and organoid culture.
The hydrogel’s synthetic chemistry provides a reproducible, animal‑component‑free alternative to basement membrane extracts, reducing lot‑to‑lot variability and enabling more reliable translational workflows. It is positioned to meet the growing demand for New Approach Methodologies (NAMs) and to support drug screening, toxicology, and personalized medicine studies that require regulatory‑aligned platforms.
The product expands Bio‑Techne’s Cultrex ECM portfolio and is expected to strengthen the company’s protein sciences and diagnostics & genomics segments. In Q4 FY2025, the Protein Sciences segment grew 6% and the Diagnostics & Spatial Biology segment also saw growth, underscoring the company’s momentum in core areas that the new hydrogel will further support.
Financially, Bio‑Techne’s Q1 FY2026 revenue fell 1% YoY to $286.56 million, below analysts’ $292.02 million estimate, largely due to a decline in North American biopharma revenue driven by order timing and funding pressures. Earnings per share of $0.42 met consensus, reflecting disciplined cost management amid the revenue dip.
Will Geist, President of the Protein Sciences segment, said the hydrogel “provides a consistent, animal‑free matrix that can replace basement membrane extracts, improving reproducibility for researchers.” CEO Kim Kelderman noted that the company is seeing stabilization in the U.S. academic market and strength from large pharmaceutical customers, and that the new product will help maintain momentum amid funding headwinds.
While no immediate market reaction to the launch has been reported, the hydrogel aligns with FDA priorities for translational outcomes and positions Bio‑Techne to capture a growing share of the synthetic hydrogel market, potentially supporting future earnings growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.